Bharat Book Bureau Provides the Treding Market Research Report on "Global Non-Alcoholic Steatohepatitis (Nash) Biomarker Market 2021-2028" under Life Science Category. The report offers a collection of superior market researach, market analysis, competitive intelligence and Market reports.
According to report, the Global Market For Non-Alcoholic Steatohepatitis (Nash) Biomarker is estimated to exhibit growth at a CAGR of 21.28% during the years 2021-2028.
The growing occurrence of NASH among people, paired with the increasing incidence rate of metabolic comorbidities, is boosting the reviewed market on a growth path. Besides, an increase in awareness regarding non-alcoholic fatty liver disease is opening new avenues for the NASH biomarker market over the projected period.
Request a Free Sample Copy Non-Alcoholic Steatohepatitis Biomarker Market [email protected]
However, side-effects of NASH therapeutics, along with the unavailability of specialized diagnostic tests for NAFLD, are hampering the expansion of the global market on a large scale.
The global market includes the Asia-Pacific, North America, Latin America, Europe, and the Middle East and Africa regions.
The Asia-Pacific is expected to observe the fastest growth rate in the non-alcoholic steatohepatitis biomarker market during the forecast period. The region’s growth can be attributed to the advancements in the healthcare infrastructure, the surge in the prevalence of NASH, and improvement in economic conditions.
Along with this, the growing healthcare awareness in emerging economies, including India and China, is expected to further influence the growth of the NASH biomarker market around the APAC region in the upcoming years.
The prominent companies engaged in the non-alcoholic steatohepatitis (NASH) biomarker include Allergan, Merck & Co, Novartis AG, Viking Therapeutics, Bristol Myers Squibb Company, Novo Nordisk, Genfit SA, Pfizer Inc, Madrigal Pharmaceuticals, Gilead Sciences Inc, AstraZeneca, Zydus Cadila, and Siemens Healthineers.
Allergan is engaged in developing, manufacturing, marketing, and distributing specialty, biosimilar, and over-the-country products. Its product portfolio includes cenicriviroc that blocks two chemokine receptors involved in inflammatory and fibrogenic pathways. This product’s phase 3 AURORA plans to enroll a large number of patients suffering from NASH. Allergen has operations in numerous regions, such as Asia-Pacific, Europe, and Latin America, serving a wide consumer base. It is headquartered in Dublin, Ireland.
TABLE OF CONTENTS
1. GLOBAL NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET - SUMMARY
2. INDUSTRY OUTLOOK
2.1. KEY INSIGHTS
2.1.1. DEMAND FOR NASH BIOMARKERS
2.1.2. UNMET MEDICAL NEEDS
2.2. IMPACT OF COVID-19 ON NON-ALCOHOLIC STEATOHEPATITIS (NASH) BIOMARKER MARKET
2.3. PORTER’S FIVE FORCES ANALYSIS
2.3.1. THREAT OF NEW ENTRANTS
2.3.2. THREAT OF SUBSTITUTE PRODUCTS
2.3.3. BARGAINING POWER OF BUYERS
2.3.4. BARGAINING POWER OF SUPPLIERS
2.3.5. COMPETITIVE RIVALRY
2.4. MARKET ATTRACTIVENESS INDEX
2.5. VENDOR LANDSCAPE
2.6. KEY MARKET STRATEGIES
2.6.1. CONTRACTS & PARTNERSHIPS
2.6.2. BUSINESS EXPANSIONS & DIVESTITURES
2.6.3. ACQUISITIONS & MERGERS
2.6.4. NEW PRODUCT LAUNCHES
2.7. MARKET DRIVERS
2.7.1. RISING PREVALENCE OF NASH
Browse our full report with Table of content:
About Bharat Book Bureau:
Bharat Book is Your One-Stop-Shop with an exhaustive coverage of 12,00,000 reports and insights that includes latest Market Study, Market Trends & Analysis, Forecasts, Customized Intelligence, Newsletters and Online Databases, Overall a comprehensive coverage of major industries with a further segmentation of 100+ subsectors.
Contact us at:
Bharat Book Bureau
Tel: +912227810772 / 27810773
Email: [email protected]